Seres Therapeutics Financials
| MCRB Stock | USD 0.86 0.05 6.17% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.94 | 2.04 |
|
|
The financial analysis of Seres Therapeutics is a critical element in measuring its lifeblood. Investors should not minimize Seres Therapeutics' ability to pay suppliers or employees on time, ensuring interest payments are not accumulating.
Net Income |
|
Seres | Select Account or Indicator |
Please note, the presentation of Seres Therapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Seres Therapeutics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Seres Therapeutics' management manipulating its earnings.
Seres Therapeutics Stock Summary
Seres Therapeutics competes with Syros Pharmaceuticals, Iovance Biotherapeutics, Veracyte, and Fate Therapeutics. Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts. Seres Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 333 people.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | USA Stock View All |
| Exchange | NASDAQ Exchange |
| ISIN | US81750R1023 |
| CUSIP | 81750R102 |
| Location | Massachusetts; U.S.A |
| Business Address | 101 Cambridgepark Drive, |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.serestherapeutics.com |
| Phone | 617 945 9626 |
| Currency | USD - US Dollar |
Seres Therapeutics Key Financial Ratios
| Return On Equity | -15.56 | ||||
| Profit Margin | (0.20) % | ||||
| Operating Margin | (0.34) % | ||||
| Price To Sales | 1.09 X | ||||
| Revenue | 126.33 M |
Seres Therapeutics Key Balance Sheet Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Total Assets | 342.9M | 354.9M | 348.8M | 358.6M | 412.4M | 225.8M | |
| Other Current Liab | 21.7M | 38.5M | 105.0M | 80.6M | 92.7M | 97.3M | |
| Net Debt | (75.3M) | (130.8M) | (440K) | 86.0M | 98.9M | 103.8M | |
| Retained Earnings | (548.8M) | (614.4M) | (864.5M) | (978.2M) | (880.4M) | (836.4M) | |
| Accounts Payable | 4.0M | 13.7M | 17.4M | 3.6M | 4.2M | 6.7M | |
| Cash | 116.0M | 180.0M | 163.0M | 128.0M | 147.2M | 93.9M | |
| Other Current Assets | 11.5M | 25.8M | 13.4M | 9.1M | 10.5M | 10.4M | |
| Total Liab | 168.2M | 223.4M | 338.0M | 403.5M | 464.0M | 487.2M | |
| Total Current Assets | 268.8M | 303.6M | 194.8M | 175.4M | 201.7M | 166.7M | |
| Common Stock | 91K | 92K | 125K | 135K | 155.3K | 163.0K | |
| Other Liab | 94.4M | 86.6M | 98.5M | 93.9M | 108.0M | 78.0M | |
| Long Term Debt | 24.6M | 24.6M | 50.6M | 101.5M | 116.8M | 122.6M | |
| Short Term Debt | 5.6M | 13.2M | 4.1M | 6.7M | 7.7M | 7.1M | |
| Net Tangible Assets | (48.3M) | 174.8M | 131.5M | 10.8M | 9.7M | 9.2M | |
| Capital Surpluse | 411.3M | 723.5M | 745.8M | 875.2M | 1.0B | 552.2M |
Seres Therapeutics Key Income Statement Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Interest Expense | 2.9M | 2.9M | 6.0M | 13.2M | 15.2M | 15.9M | |
| Operating Income | (88.1M) | (64.5M) | (246.5M) | (108.0M) | (97.2M) | (102.0M) | |
| Ebit | (86.2M) | (65.9M) | (249.4M) | (100.5M) | (90.5M) | (95.0M) | |
| Research Development | 90.6M | 141.9M | 172.9M | 145.9M | 167.7M | 87.5M | |
| Ebitda | (77.3M) | (56.7M) | (237.5M) | (94.3M) | (84.9M) | (89.1M) | |
| Income Before Tax | (89.1M) | (65.6M) | (250.2M) | (113.7M) | (102.4M) | (107.5M) | |
| Net Income | (86.5M) | (61.5M) | (253.8M) | (113.7M) | (102.4M) | (107.5M) | |
| Income Tax Expense | (2.7M) | (4.1M) | 3.7M | 14.9M | 17.2M | 18.0M | |
| Total Revenue | 33.2M | 144.9M | 7.1M | 126.3M | 145.3M | 152.5M | |
| Cost Of Revenue | 90.6M | 1.7M | 1.0M | 704K | 633.6K | 601.9K | |
| Interest Income | 946K | 2.9M | 3.1M | 6.7M | 7.8M | 8.1M | |
| Net Interest Income | (2.0M) | (40K) | (3.0M) | (4.3M) | (3.9M) | (3.7M) |
Seres Therapeutics Key Cash Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Change In Cash | 50.9M | 72.0M | (16.8M) | (35.1M) | (31.6M) | (30.0M) | |
| Free Cash Flow | (94.2M) | (2.9M) | (238.6M) | (125.3M) | (112.8M) | (107.2M) | |
| Depreciation | 6.6M | 5.9M | 6.6M | 6.2M | 7.2M | 4.9M | |
| Other Non Cash Items | 3.3M | 2.0M | 7.6M | 15.0M | 17.3M | 18.1M | |
| Capital Expenditures | 591K | 9.6M | 9.8M | 8.0M | 9.2M | 5.8M | |
| Net Income | (89.1M) | (65.6M) | (250.2M) | (113.7M) | (102.4M) | (107.5M) | |
| End Period Cash Flow | 116.0M | 188.0M | 171.2M | 136.2M | 156.6M | 96.2M | |
| Investments | (158.3M) | 73.7M | 92.2M | 17.4M | 20.0M | 21.0M | |
| Change To Netincome | 8.7M | 8.8M | 24.3M | 25.5M | 29.3M | 16.2M |
Seres Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Seres Therapeutics's current stock value. Our valuation model uses many indicators to compare Seres Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Seres Therapeutics competition to find correlations between indicators driving Seres Therapeutics's intrinsic value. More Info.Seres Therapeutics is rated below average in return on equity category among its peers. It is regarded second in return on asset category among its peers . At present, Seres Therapeutics' Return On Equity is projected to slightly decrease based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Seres Therapeutics' earnings, one of the primary drivers of an investment's value.Seres Therapeutics Systematic Risk
Seres Therapeutics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Seres Therapeutics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was thirty with a total number of output elements of thirty-one. The Beta measures systematic risk based on how returns on Seres Therapeutics correlated with the market. If Beta is less than 0 Seres Therapeutics generally moves in the opposite direction as compared to the market. If Seres Therapeutics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Seres Therapeutics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Seres Therapeutics is generally in the same direction as the market. If Beta > 1 Seres Therapeutics moves generally in the same direction as, but more than the movement of the benchmark.
Seres Therapeutics Thematic Clasifications
Seres Therapeutics is part of Pharmaceutical Products investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. USA Equities from Pharmaceutical Products industry as classified by Fama & French. Fama and French investing themes focus on testing asset pricing under different economic assumptions
This theme covers USA Equities from Pharmaceutical Products industry as classified by Fama & French. Fama and French investing themes focus on testing asset pricing under different economic assumptions. Get More Thematic Ideas
| Pharmaceutical Products | View |
Today, most investors in Seres Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Seres Therapeutics' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Seres Therapeutics growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
Seres Therapeutics January 30, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Seres Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Seres Therapeutics. We use our internally-developed statistical techniques to arrive at the intrinsic value of Seres Therapeutics based on widely used predictive technical indicators. In general, we focus on analyzing Seres Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Seres Therapeutics's daily price indicators and compare them against related drivers.
| Downside Deviation | 4.85 | |||
| Information Ratio | 0.0323 | |||
| Maximum Drawdown | 28.84 | |||
| Value At Risk | (6.78) | |||
| Potential Upside | 15.58 |
Complementary Tools for Seres Stock analysis
When running Seres Therapeutics' price analysis, check to measure Seres Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Seres Therapeutics is operating at the current time. Most of Seres Therapeutics' value examination focuses on studying past and present price action to predict the probability of Seres Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Seres Therapeutics' price. Additionally, you may evaluate how the addition of Seres Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm |